The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.
 
Colette Shen
Consulting or Advisory Role - GT Medical Technologies; Nanobiotix
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - In Vitro Microphysiological System For High Throughput 3D Tissue Organization And Biological Function, patent issued 12/06/16 --no royalties (I); Microscopy with Lattice Light Sheets and Point Accumulation for Imaging and Nanoscale Topography, patent filed 12/7/15 --no royalties (I)
Travel, Accommodations, Expenses - Nanobiotix
 
Jessica M. Frakes
No Relationships to Disclose
 
Trevor G Hackman
Honoraria - Nanobiotix
 
Jiaxin Niu
Consulting or Advisory Role - AstraZeneca; Bristol Mers Squibb; Daiichi Sankyo; G1 Therapeutics; Johnson & Johnson; Mirati Therapeutics; Pfizer; Sanofi; Takeda
 
Jared Weiss
Stock and Other Ownership Interests - Achilles Therapeutics (I); Enfuego Therapeutics; Lyell Immunopharma; Nektar; Nuvalent, Inc.; Vertex; Vesselon
Consulting or Advisory Role - abbvie; Amgen; AstraZeneca; BeiGene; EMD Serono; G1 Therapeutics; Genentech; Genmab; Gilead Sciences; Jounce Therapeutics; Merck; Nanobiotix; PDS Biotechnology; Regeneron; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); G1 Therapeutics (Inst); Immunicum (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); PDS Biotechnology (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Jimmy J. Caudell
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - UpToDate
 
George Q Yang
No Relationships to Disclose
 
Tanguy Y. Seiwert
Honoraria - Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bayer; BioNTech SE; BostonGene; CUE Biopharma; Eisai; Exelixis; Innate Pharma; IO Biotech; ITeos Therapeutics; Merck; Nanobiotix; Regeneron; Sanofi; Seattle Genetics/Astellas; Surface Oncology; VIR Biotechnology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cue Biopharma (Inst); Dracen (Inst); Genentech/Roche (Inst); Merck (Inst); Nanobiotix (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - BostonGene; Coherus Biosciences; Nanobiotix
 
Septimiu Murgu
No Relationships to Disclose
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Seagen; Veru
Consulting or Advisory Role - MyCareGorithm
Travel, Accommodations, Expenses - A2Bio
 
David Rolando
Employment - Nanobiotix
 
Pavel Tyan
Employment - Nanobiotix
 
Omar I Vivar
Employment - Nanobiotix
 
Zhen Gooi
Honoraria - Nanobiotix
 
Aditya Juloori
No Relationships to Disclose
 
Ari Joseph Rosenberg
Stock and Other Ownership Interests - Galectin Therapeutics; Privo Technologies
Consulting or Advisory Role - Astellas Pharma; Eisai; EMD Serono; Nanobiotix; Novartis; Regeneron; Vaccitech
Speakers' Bureau - Coherus Biosciences
Research Funding - Abbvie (Inst); BeiGene (Inst); Bristol-Myers Squibb/Celgene (Inst); EMD Serono (Inst); Hookipa Biotech (Inst); Purple Biotech (Inst)